TPIDB > 臨床試驗主持人
臨床試驗主持人
發表文獻
23筆
1
Hsu WF, Hsu CY, Yen AM, Chen SL, Chiu SY, Fann JC, Lee YC, Chiu HM, Chen HH. Classifying interval cancers as false negatives or newly occurring in fecal immunochemical testing. J Med Screen. 2021 Sep;28(3):286-294. doi: 10.1177/0969141320986830. Epub 2021 Jan 18. PMID: 33461420.
2
Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, Chen YR, Chuang SL, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chan CC, Graham DY, Chen HH, Lee YC. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021 Feb;70(2):243-250. doi: 10.1136/gutjnl-2020-322200. Epub 2020 Aug 13. PMID: 32792335; PMCID: PMC7815911.
3
Su WW, Lee YH, Yen AM, Chen SL, Hsu CY, Chiu SY, Fann JC, Lee YC, Chiu HM, Hsiao SC, Hsu TH, Chen HH. Impact of treatment delay on survival of oral/oropharyngeal cancers: Results of a nationwide screening program. Head Neck. 2021 Feb;43(2):473-484. doi: 10.1002/hed.26504. Epub 2020 Oct 13. PMID: 33047420; PMCID: PMC7820997.
4
Chen CC, Luo JC, Fang YJ, Lee JY, Kuo CC, Yang TH, Chiu MC, Yu JJ, Bair MJ, Chen PY, Chou CK, Chen CY, Chang CY, Hsu YC, Tseng CH, Hsu WF, Hu WH, Tsai MH, Hsieh CL, Chen MJ, Shun CT, Liu TY, Lee YC, Liou JM, Wu MS; and for the Taiwan Gastrointestinal Disease and Helicobacter Consortium. Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial. Therap Adv Gastroenterol. 2020 Jul 31;13:1756284820927306. doi: 10.1177/1756284820927306. PMID: 32821287; PMCID: PMC7406927.
5
Wu WK, Panyod S, Liu PY, Chen CC, Kao HL, Chuang HL, Chen YH, Zou HB, Kuo HC, Kuo CH, Liao BY, Chiu THT, Chung CH, Lin AY, Lee YC, Tang SL, Wang JT, Wu YW, Hsu CC, Sheen LY, Orekhov AN, Wu MS. Characterization of TMAO productivity from carnitine challenge facilitates personalized nutrition and microbiome signatures discovery. Microbiome. 2020 Nov 19;8(1):162. doi: 10.1186/s40168-020-00912-y. PMID: 33213511; PMCID: PMC7676756.
6
Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 Dec;69(12):2093-2112. doi: 10.1136/gutjnl-2020-322368. Epub 2020 Oct 1. PMID: 33004546.
7
Bair MJ, Chuang SL, Lei WY, Chen CL, Tian HW, Chiang TH, Su WW, Lin CC, Chung Lo YT, Jou YY, Wu CY, Chia SL, Wu MS, Chen HH, Chu CH, Lee YC, Wang YW. Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer. J Gastroenterol Hepatol. 2020 Apr;35(4):609-616. doi: 10.1111/jgh.14898. Epub 2019 Dec 4. PMID: 31677184.
8
Liou JM, Lee YC, Wu MS. Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. J Gastroenterol Hepatol. 2020 Jul;35(7):1107-1116. doi: 10.1111/jgh.14992. Epub 2020 Feb 14. PMID: 31984532.
9
Chiang TH, Maeda M, Yamada H, Chan CC, Chen SL, Chiu SY, Chen YN, Chou YH, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chen HH, Ushijima T, Graham DY, Lee YC. Risk stratification for gastric cancer after Helicobacter pylori eradication: A population-based study on Matsu Islands. J Gastroenterol Hepatol. 2021 Mar;36(3):671-679. doi: 10.1111/jgh.15187. Epub 2020 Jul 24. PMID: 32671873.
10
Tu CH, Kao JY, Tseng PH, Lee YC, Chiang TH, Chen CC, Wang HP, Chiu HM, Wu MS. Early timing of single balloon enteroscopy is associated with increased diagnostic yield in patients with overt small bowel bleeding. J Formos Med Assoc. 2019 Dec;118(12):1644-1651. doi: 10.1016/j.jfma.2019.01.003. Epub 2019 Jan 17. PMID: 30661919.
